Before you can access ASH's online program, you must agree to the following:
Last updated January 16, 2009. Please note that this site represents the latest program changes
and differs from the print version in some details.

732.O2.8 Alternative Donor Transplantation - Disease Specific Outcomes and HLA

Monday, December 8, 2008: 3:30 PM-5:30 PM
304-306-308 - South (Moscone Center)
Moderators:
J. Koreth and William Arcese, MD
3:30 PM
The Clinical Significance of Matching for Alleles at the Low Expression HLA Loci DP, DQ and DRB3/4/5 in Unrelated Hematopoietic Stem Cell TransplantationClinically Relevant Abstract

Marcelo Fernandez-Vina, PhD1*, John Klein, PhD2*, Michael D Haagenson, MS3*, Stephen R Spellman, MS4*, Stephanie J. Lee, MD, MPH5, Claudio Anasetti, MD6, Lee Ann Baxter-Lowe, PhD7, Pedro Cano, MD1*, Neal Flomenberg, MD, FACP8*, Mary M. Horowitz, MD, MS2, Carolyn K Hurley, PhD9*, Machteld Oudshoorn, PhD10*, Effie W Petersdorf, MD5*, Michelle Setterholm4*, Richard Champlin, MD1 and Marcos De Lima, MD1

1University of Texas MD Anderson Cancer Center, Houston, TX
2Medical College of Wisconsin, Center for International Blood and Marrow Transplant Research, Milwaukee, WI
3Center for International Blood and Marrow Transplant Research, Minneapolis, MN
4National Marrow Donor Program, Minneapolis, MN
5Fred Hutchinson Cancer Research Center, Seattle, WA
6H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
7University of California San Francisco, San Francisco, CA
8Thomas Jefferson University, Philadelphia, PA
9Georgetown University Medical Center, Washington, DC
10Europdonor Foundation, Leiden, Netherlands

3:45 PM
NON-Permissive HLA-DPB1 T CELL Epitope Disparities Correlate with Engraftment and Survival after Unrelated Stem Cell Transplantation

Roberto Crocchiolo, M.D.1*, Elisabetta Zino, M.D.1*, Nicoletta Sacchi, Ph.D.2*, Jessica Marcon, M.D.1*, Simona Pollichieni, Ph.D.2*, Rosi Oneto, Ph.D.1*, Giuseppe Bandini, M.D.1*, Andrea Bacigalupo, MD3, Fabio Ciceri, M.D.1* and Katharina Fleischhauer, M.D.1*

1GITMO, Genova, Italy
2IBMDR, Genova, Italy
3Hem-Onc, Ospedale S. Martino, Genova, Italy

4:00 PM
Evaluation of Human Leukocyte Antigen (HLA) Matching Requirements for Unrelated Peripheral Blood Stem Cell (PBSC) Transplantation

Ann E Woolfrey, MD1*, John Klein, PhD2*, Michael D Haagenson, MS3*, Stephen R Spellman, MS4*, Minoo Battiwalla, MD5, James L. Gajewski, MD6, Gregory A. Hale, MD7*, John Horan, MD, MPH8*, Carolyn K Hurley, PhD9*, Craig Kollman, PhD10*, Susana Marino, MD, PhD11*, Machteld Oudshoorn, PhD12*, Effie W Petersdorf, MD1*, Olle Ringdén, MD, PhD13*, Michelle Setterholm4* and Stephanie J. Lee, MD, MPH1

1Fred Hutchinson Cancer Research Center, Seattle, WA
2Medical College of Wisconsin, Milwaukee, WI
3CIBMTR, Minneapolis, MN
4National Marrow Donor Program, Minneapolis, MN
5Roswell Park Cancer Institute, Buffalo, NY
6Fox Chase Temple BMT Program, Philadelphia, PA
7St. Jude Children's Research Hospital, Memphis, TN
8Emory School of Medicine/Children's Healthcare of Atlanta, Atlanta, GA
9Georgetown University Medical Center, Washington, DC
10Jaeb Center for Health Research, Tampa, FL
11University of Chicago Medical Center, Chicago, IL
12Europdonor Foundation, Leiden, NL.
13Karolinska University Hospital Huddinge, Stockholm, Sweden

4:15 PM
Factors Determining Survival after Unrelated Donor Stem Cell Transplantation in Primary Refractory Acute Myeloid LeukemiaClinically Relevant Abstract

Charles F. Craddock, BM, MRCP, MRCPath1, Myriam Labopin2*, J.ürgen Finke3, Gerhard Ehninger, MD4, Donald Bunjes5*, Hans-Jochem Kolb6*, Hildegard Greinix7*, Axel Zander8*, Emmanuelle Polge2*, Christoph Schmid6*, Dietrich Beelen9* and Vanderson Rocha, ASH, member10*

1Center for Clinical Hematology, Birmingham, ARRAY(0xc83fd08)
2EBMT Paris Office, Paris, France
3Hematology/Oncology, University Medical Center Freiburg, Freiburg, Germany
4Universitatsklinikum Carl Gustav Carus, Dresden, Germany
5Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany
6Department of Medicine, University of Munich
7Mediziniache University
8Haematology, University Hospital Eppendorf, Hamburg, Germany
9Department of Bone Marrow Transplantation, University Hospital Essen
10BMT unit, Hopital Saint Louis APHP and Université Paris VII, Paris, France

4:30 PM
Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)Clinically Relevant Abstract

Peter Dreger, MD1*, Stephan Stilgenbauer, MD, PhD2, Sebastian Boettcher, MD3*, Matthias Ritgen3*, Sascha Dietrich1*, Donald Bunjes, MD2*, Dietrich Wilhelm Beelen, MD4*, Sandra Cohen, MD, FRCP(C)5, Ute Hegenbart1*, Joerg Schubert, MD6*, Michael Stadler, MD7*, Bertram Glass, MD, PhD8*, Andreas Burchert, MD9, Lutz Uharek10*, Michael Hallek11, Michael Kneba, MD, PhD3*, Norbert Schmitz, MD8* and Hartmut Döhner2

1Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany
2Internal Medicine III, University of Ulm, Ulm, Germany
3Department of Internal Medicine II, University of Schleswig-Holstein, Kiel, Germany
4KMT Unit, University, Essen, Germany
5Maisonneuve Rosemont Hospital, Montreal, QC, Canada
6Internal Medicine I, Saarland University Medical School, Homburg/Saar, Germany
7Hematology & Oncology, Medical Center University of Hannover, Hannover, Germany
8Hematology and Stem Cell Transplantation, ASKLEPIOS Klinik St. Georg, Hamburg, Germany
9Hem./Onc./Immunology, University of Marburg, Marburg, Germany
10Medical Clinic III - Hematology and Oncology, Charité University Medicine Berlin, Germany
11Dept. of Internal Med. I, University of Cologne, Cologne, Germany

4:45 PM
Standard and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantations (HSCT) from Related and Unrelated Donors for Chronic Lymphocytic Leukemia (CLL). a Long-Term Follow-up (10 years) Study from the EBMT Registry. (CLL Sub-Committee on Behalf of EBMT CLWP)Clinically Relevant Abstract

Mauricette Michallet, MD, PhD1, Quoc Hung Le, MD1*, Peter Dreger2*, Mohamad Sobh, PhD1*, Dietger Niederwieser, MD3*, Vladimir Koza, MD4*, Tapani Ruutu5, Nigel H. Russell, MD6, Leo Verdonck7*, Donald Milligan, MD, MBChB8, Nathalie Dhedin9*, Tomas Kozak, MD, PhD10*, Marc Boogaerts, MD, PhD11, Juergen Finke12, Nathalie Tedone1*, Anja Van biezen13*, Ronald Brand14* and Theo de Witte on behalfhe European Group for Blood and Marrow Transplantation15*

1Hematology, Hopital Edouard Herriot, Lyon, Cedex 03, France
2Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
3University of Leipzig, Leipzig, Germany
4Dept. of Hematology and Oncology, University Hospital Pilsen, Pilsen, Czech Republic
5Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
6Centre for Clinical Haematology, Nottingham University Hospital, Nottingham, ARRAY(0xc1c3fa4)
7Haematology, University Medical Centre, Utrecht, Netherlands
8Dept. of Hematology, Birmingham Heartlands Hospital, Birmingham, ARRAY(0xc1edb84)
9Service d'Hématologie Clinique, Hôpital Pitié-Salpêtrière, Paris, France
10Department Of Clinical Hematology,, University Hospital Kralovske Vinohrady, Prague, Czech Republic
11Hematology, U.Z. Gasthuisberg, Leuven, Belgium
12Dept. of Hematology/Oncology, University Medical Center Freiburg, Germany
13CLWP, Leiden
14CLWP, Leiden, Netherlands
15UMC St Radboud, Nijmegen, Netherlands

5:00 PM
Significant Reduction of Treatment Related Mortality after Stem Cell Transplantation in 647 Children and Adolescents with ALL within BFM Trials during the Last 12 Years: A Long Term Analysis from 1996 to 2007Clinically Relevant Abstract

André Schrauder1*, Martin Schrappe1, Arend Stackelberg2*, Peter Bader3*, Wolfgang Holter4*, Rupert Handgretinger5*, Wolfram Ebell6*, Dagmar Dilloo7, Tayfun Güngör8*, Monika Fuehrer9*, Hartmut Kabisch10*, Martin Zimmermann11*, Ulrike Poetschger12*, Karl-Walter Sykora11* and Christina Peters13*

1Pediatrics, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany
2Department of Pediatric Oncology/Hematology, Charité - Medical University, Berlin, Germany
3Pediatric Hematology/Oncology, Johann Wolfgang Goethe University, Frankfurt, Germany
4Pediatric Hematology/Oncology, University Erlangen, Erlangen, Germany
5Pediatric Hematology, University Clinic Tuebingen, Tuebingen, Germany
6Pediatric Stem Cell Transplantation, Charite Campus Virchow, Berlin, Germany
7Heinrich-Heine University, Dusseldorf, Germany
8Pediatric Hospital, University Zuerich, Zuerich, Switzerland
9Pediatric Hematology/Oncology, University Clinic Munich, Munich, Germany
10Pediatric Hematology Oncology, University Hospital, Hamburg, Germany
11Pediatric Hematology/Oncology, Medical School Hannover, Hannover, Germany
12Children Cancer Research Institute, Vienna, Austria
13St. Anna Children's Hospital, Vienna, Austria

5:15 PM
Clinical Outcome of 640 Children with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Treated Between 1995 and 2005Clinically Relevant Abstract

Maurizio Aricò, MD1, Martin Schrappe, MD2, Stephen Hunger, MD3, William L. Carroll, MD4, Valentino Conter, MD5*, Paola Di Lorenzo6*, Atsushi Manabe, MD, PhD7, Vaskar Saha8*, Andre Baruchel, MD9, Kim Vettenranta, MD, PD10, Masahiro Tsuchida11, Yves Benoit12*, Rob Pieters, MD, PhD13, Gabriele Escherich14*, Lewis B. Silverman, MD15, Ching-Hon Pui, MD16 and Maria Grazia Valsecchi17*

1Pediatric Hematology Oncology, Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, Florence, Italy
2Pediatrics, University Medical Center, Kiel, Germany
3Pediatric Heme/Onc/BMT, Univ of Colorado College of Medicine, Aurora, CO
4NYU School of Medicine, New York, NY
5Department of Pediatrics, University of Milano-Bicocca, Ospedale S. Gerardo, Monza, Italy
6Dept of Clinical and Preventive Medicine, Universita' Milano-Bicocca, Monza, Italy
7Tokyo Children's Cancer Study Group, Japan
8Children's Cancer and Leukaemia Group
9Dept. of Pediatric Hematology, Hopital Saint Louis, Paris, France
10University of Helsinki Children's Hosp., Helsinki, Finland
11Dept. of Pediatrics, Ibaraki Children's Hospital, Mito, Japan
12European Organisation for Research and Treatment of Cancer, France
13Dept. of Pediatric Hem./Onc., Erasmus MC, Rotterdam, Netherlands
14Universitätsklinikum Hamburg-Eppendorf, Germany
15Pediatric Oncology, Dana-Farber Cancer Inst., Boston, MA
16Dept. of Onc., St. Jude Children's Rsch./Hosp., Memphis, TN
17Dept of Clinical and Preventive Medicine, Università Milano Bicocca, for the International Childhood Acute Lymphoblastic Leukemia Study Group, Monza, Italy

*signifies non-member of ASH